ArticleCureus2024
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Child-Pugh Class C As Bridge Therapy Before Liver Transplantation.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a rising global health concern, frequently developing in patients with cirrhosis. Stereotactic body radiotherapy (SBRT) offers an effective treatment option for localized HCC, utilizing advanced imaging and planning technologies to accurately target tumors while sparing healthy tissues. It serves as an alternative when other locoregional therapies are contraindicated. We present the case of a 58-year-old male with HCC exceeding 5 cm and classified as Child-Pugh Class C. Following a failed attempt at transarterial chemoembolization (TACE) due to deteriorating liver function, SBRT was selected as an alternative bridging therapy. The patient received a total dose of 30 Gy in five fractions. Throughout the treatment, he experienced no significant toxicity, and post-SBRT imaging indicated gradual tumor regression. Seven months post-SBRT, the patient successfully underwent deceased-donor liver transplantation. Pathological examination of the explanted liver revealed necrotic nodules, indicating a positive response to SBRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.